The following information was submitted:

Name & Sponsoring Organization

First Name: Albert
Last Name: Li
Are you submitting comments on behalf of a sponsoring organization? No
If yes, please enter the name of the organization:

Comments and Questions

1. Do you have comments on the priority areas for the development and validation of alternative test methods listed above?

   The previous priority list does not include two major toxicity that affects the human populations: liver toxicity (hepatotoxicity), kidney toxicity (nephrotoxicity), and heart toxicity (cardiotoxicity).

2. Considering available science and technology, what development, translation, and validation activities are most likely to have the greatest impacts within the next five years on refining, reducing, or replacing animal use?

   Develop logical approaches to correlate in vitro results to in vivo.

3. What research and development activities hold the greatest promise in the long-term for refining, reducing, or replacing animal use?

   Application of human-cell based technologies (e.g. human hepatocytes) in the evaluation of the effects of toxicants on humans; application of co-culture systems (e.g. Integrated Discrete Multiple Organ Co-culture (IdMOC) to allow evaluation of multiple organ toxicity.

4. What are appropriate measures for evaluating progress in enhancing the development and use of alternative test methods?

   Actual adoption of the technologies for decision making processes is the ultimate measure of success. Examples are: applications in product development in industry; acceptance of data for product safety evaluation by regulatory agencies.